Boehringer Ingelheim struck an agreement with the U.S. administration to join the TrumpRx direct‑purchase platform and invest $10 billion in U.S. operations through 2028. The deal includes commitments to expand manufacturing capacity, a $1 billion capital expenditure component, and protections from Section 232 tariff actions. The company framed the move as advancing supply‑chain resilience and lowering drug costs via direct purchasing. Jean‑Michel Boers, president and CEO of Boehringer Ingelheim USA, said the pact will help patients access treatments while supporting U.S. manufacturing investment.